- PLN83.04m
- PLN84.46m
- PLN5.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.19 | ||
| Price to Tang. Book | 37.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 14.48 | ||
| EV to EBITDA | 179.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.17% | ||
| Return on Equity | -4.69% | ||
| Operating Margin | -18.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 3.23 | 6.02 | 12.71 | 6.73 | 5.74 | n/a | n/a | 115.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +36.9 | +90.02 | -86.84 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medapp SA is a Poland-based company engaged in the software development. The Company provides a software application, named Carna Life, which is used in telemedicine sector. Carna Life serves as communication channel between doctors and patient. Carna Life is a telemedicine system that enables patients to upload test results and receive doctor's interpretation. The application operates in online (upload and download of data) and offline (review of data) mode. Carna Life provides statistics, graphic visualizations and tables with interpreted data. The Company is controlled by Moonrock Enterprise SA.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 26th, 2010
- Public Since
- October 19th, 2011
- No. of Employees
- 18
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 250,132,454
- Address
- Armii Krajowej 25, KRAKOW, 30-150
- Web
- https://medapp.pl/
- Phone
- +48 228455555
- Auditors
- KPW Audytor sp. zoo
Upcoming Events for MDA
Similar to MDA
11 Bit Studios SA
Warsaw Stock Exchange
3R Games SA
Warsaw Stock Exchange
All In! Games SA
Warsaw Stock Exchange
Ailleron SA
Warsaw Stock Exchange
Aiton Caldwell SA
Warsaw Stock Exchange
FAQ
As of Today at 19:14 UTC, shares in Medapp SA are trading at PLN0.33. This share price information is delayed by 15 minutes.
Shares in Medapp SA last closed at PLN0.33 and the price had moved by +3.11% over the past 365 days. In terms of relative price strength the Medapp SA share price has underperformed the FTSE Global All Cap Index by -3.2% over the past year.
There is no consensus recommendation for this security.
Medapp SA does not currently pay a dividend.
Medapp SA does not currently pay a dividend.
Medapp SA does not currently pay a dividend.
To buy shares in Medapp SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN0.33, shares in Medapp SA had a market capitalisation of PLN83.04m.
Here are the trading details for Medapp SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: MDA
Based on an overall assessment of its quality, value and momentum Medapp SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medapp SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -27.62%.
As of the last closing price of PLN0.33, shares in Medapp SA were trading -13.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medapp SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN0.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Medapp SA's directors